PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1364689
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1364689
Baculovirus Expression System Market size was valued at USD 350.7 Million in 2022, expanding at a CAGR of 9.2% from 2023 to 2030.
The baculovirus expression system has been widely employed in the expression of recombinant proteins within insect cells for many years. Recombinant Baculovirus vectors for temporary and stable gene delivery into various mammalian cell lines have recently been developed. The Baculovirus Expression System is a potent and adaptable platform for producing recombinant proteins, particularly those that require specific post-translational modifications. Its powers go beyond just protein expression, with potential medicinal applications as well.
There has been a rise in research into novel proteins, enzymes, and other compounds that can act as possible treatments or diagnostics for lifestyle disorders. This necessitates systems capable of producing these proteins in their active forms, in adequate quantities, and with the necessary post-translational modifications. Lifestyle diseases, often known as non-communicable diseases (NCDs), include cardiovascular disease, diabetes, obesity, and some malignancies. Because of this spike, there is an urgent need for novel and effective therapeutic methods.
According to the World Health Organization, each year, 17 million people die from non-communicable diseases before age 70; 86% of these premature deaths occur in low- and middle-income countries. As baculoviruses are being researched for possible applications in gene therapy, any breakthroughs could open up new business opportunities for BES. However, The BES process, which involves recombination, virus amplification, and protein harvesting, can be complex and lengthy, which may discourage some potential users.
The Global Baculovirus Expression System Market is segmented on the basis of Application, End-User, and Region.
The market is divided into three categories based on Application: Therapeutic, Research, and Industrial. The therapeutic segment dominates the market. The BES's capacity to introduce mammalian-like post-translational modifications has made it a favored alternative for therapeutic protein synthesis. To be useful and safe in therapeutic applications, these proteins frequently require specialized changes.
The market is divided into two categories based on End-User: Pharmaceutical and Biotechnology companies, Contract research organizations, contract manufacturing organizations, Academic research institutes, and Others. pharmaceutical and Biotechnology companies dominate the market growth. They utilize BES for drug discovery, vaccine development, and the manufacture of therapeutic proteins. Given the size of their operations and the commercial relevance of the products they manufacture; they account for a sizable amount of market demand.
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the market due to the high growth of the pharmaceutical and biotechnological sectors. U.S. pharmaceutical and biotech companies are among the top global spenders on research and development. This investment drives the demand for effective protein expression platforms, including BES. According to pharmaceutical industry statistics, The U.S. is expected to spend USD605-USD635 billion on medicine in 2025. And there are more than 310,574 pharmacists currently employed in the United States. Europe is expected to second largest region for the growth of this market, due to increasing funding for protein research.
The Baculovirus Expression System (BES) market has a diverse set of players offering products, services, and solutions suited to the BES. These players compete on the basis of product quality, innovation, pricing, and after-sales services. Companies are constantly striving to increase the efficiency of their BES products in order to achieve higher yields and better protein quality. Companies are striving to expand their reach as a biotechnology research and use develop globally, particularly in emerging areas where demand is expanding. For example, Merck provides tools and services related to the BES. Their offerings include kits, reagents, and services tailored for maximum protein yield and quality.
On May 2, 2018, Historically, undefined insect media components such as yeast late have made it challenging to achieve consistent results and protein yields across multiple experiments. These factors can significantly slow vaccine development at a time when manufacturers are under pressure to develop vaccines faster and more efficiently. Focused on removing barriers to vaccine development and production, Thermo Fisher Scientific announced today its Gibco ExpiSf system, the first-ever chemically defined insect protein expression system.
The scope of this report covers the market by its major segments, which include as follows: